SAN DIEGO, July 28, 2022–(BUSINESS WIRE)–Crown Bioscience, a JSR Life Sciences company, today announced that it has restructured its commercial leadership team by accepting a new Chief Business Officer (CBO) position and investing more in business skills.
This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20220728005027/fr/
Effective immediately, Michael Prosser is promoted to Chief Commercial Officer. Michael has been with Crown Bioscience for over ten years and has held various operational and business leadership positions, most recently serving as Senior Vice President, Business and Strategic Development. (Photo: BusinessWire)
Effective immediately, Michael Prosser is promoted to Chief Business Officer. Michael has been with Crown Bioscience for over ten years, where he held various operational and commercial management positions. Most recently, he held the position of Senior Vice President of Business and Strategic Development.
The company’s continued growth has resulted in the creation of three new positions within the commercial team that will report to Mr. Prosser. Alex Slater, who joined the company last year, leads APAC business development as vice president of global business development; Dr. Jonny McMichael has been named vice president of customer experience and enablement; and Dr. Achim Quandt has joined the company as Executive Director of Product Management.
“Crown Bioscience has experienced significant growth in recent years, consistently exceeding its annual growth target, and in fiscal 2021, we were very pleased to record booking growth exceeding 40%,” said CEO, Armin Spura. “With these changes announced today and Michael’s continued leadership, we are confident we are building a commercial team that optimally positions Crown Bioscience for our next phase of growth.”
Michael Prosser, CBO, said, “It is an honor to be asked to lead Crown Bioscience’s next stage of business growth. The success we have had so far is directly attributable to our relentless focus on customer experience, product innovation and setting new industry-leading quality standards, and I am delighted to be working closed with this new team and structure as we strive to continuously improve all of these areas.”
The company won more than 400 new customers in fiscal 2021, and to meet this increased demand, it has accelerated investments in its global network, with renovations now complete in APAC labs and, in particular, the creation of a joint venture with sister company MBL in Japan. Parallel investments are also planned in Europe and the United States for site extensions and strategic acquisitions.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) that provides preclinical and translational platforms to advance oncology, immuno-oncology and immune-mediated inflammatory diseases. The company is the only preclinical CRO providing tumor organoid services that uses HUB technology and has the largest commercially available PDX collection in the global market. Crown Bioscience helps deliver superior drug candidates so patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience owns nine sites in the United States, Europe and Asia. For more information: https://www.crownbio.com.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220728005027/en/